News for Joinn Laboratories (China) Co.,Ltd. (6127.HK)

WuXi Biologics seems to be moderating its pace of investments in the US market. Read why I have a mixed view of WXIBF stock as a potential investment.

Key Takeaways: Joinn Lab is heading for a loss in the second quarter, weighing on its profit performance for the half year, as the market value of its lab monkeys tumbled Many of its investors have sold off blocks of shares since last April By Molly Wen

The leading provider of pre-clinical drug research has predicted its first-half profits will plummet between 70% and 80% due to the falling value of its lab animals.

Key Takeaways： As well as tapping strategic investors, Viva Biotech is planning to list its drug research subsidiary on a Chinese exchange by the end of 2026 A sinking share price has piled pressure on the company to buy back its convertible bonds, hence the need for funds By Molly Wen

As well as tapping strategic investors, Viva Biotech is planning to list its drug research subsidiary on a Chinese exchange by the end of 2026.

Joinn Lab’s net profit in the first three quarters of this year surpassed the figure for all 2021 as the company rapidly expanded its capacity.

Key Takeaways: Joinn Lab’s net profit in the first three quarters of this year surpassed the figure for all 2021 as the company rapidly expanded its capacity The company is strongly positioned due to high barriers to entry, and a broad presence in its industry chain through its acquisition of lab animal suppliers